All In Biotech

Drug Trial Radar · NCT06033742

A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HS-10374 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Sep 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

84

Actual

Start

Nov 13, 2021

Primary completion

Mar 24, 2023

Study completion Mar 24, 2023

Sponsor

Sponsor type
Industry
First posted
Sep 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this first-in-human study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of HS-10374 in healthy subjects.

Conditions

  • Psoriasis

Interventions

  • HS-10374 tabletsDrug

    Single or multiple dosing of HS-10374 orally in a fasting state

  • HS-10374-matched placebo tabletsDrug

    Single or multiple dosing of HS-10374-matched placebo orally in a fasting state

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence, severity and association with the study drug of adverse events (AEs), serious AEs (SAEs), and AEs leading to discontinuationTime frame: Day 1 up to Day 12 (SAD), Day 1 up to Day 42 (MAD)
  2. Number of participants with clinical laboratory abnormalitiesTime frame: Day 1 up to Day 12 (SAD), Day 1 up to Day 42 (MAD)
  3. Number of participants with abnormalities of vital signsTime frame: Day 1 up to Day 12 (SAD), Day 1 up to Day 42 (MAD)
  4. Number of participants with abnormalities of physical examinationTime frame: Day 1 up to Day 12 (SAD), Day 1 up to Day 42 (MAD)
  5. Number of participants with abnormalities of electrocardiogram (ECG) parametersTime frame: Day 1 up to Day 12 (SAD), Day 1 up to Day 42 (MAD)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Huashan Hospital Affiliated to Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.